Skip to content Skip to footer
Subscribe Now
NEWS

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
January 8, 2025

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots:  The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024  Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion   Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
January 8, 2025

Read more

Key Biosimilars Events of December 2024
INSIGHTS+

Key Biosimilars Events of December 2024

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025

Read more

Key Biosimilars Events of December 2024
INSIGHTS+

Key Biosimilars Events of December 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at EADV Congress 2024: Uwe Gudat in a Stimulating Dialogue Exchange with PharmaShots

Shots:  At the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Biocon Biologics presented results from two pivotal P-III clinical studies. These studies supported the interchangeability between Humira and adalimumab-fkjp, as well as the biosimilarity between Bmab 1200 and Stelara for the treatment of patients with moderate-to-severe plaque psoriasis  In an engaging conversation with…
January 6, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (December 30th, 2024 – January 03rd, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:     Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular Atrophy (SMA) Read More: Novartis CARsgen Therapeutics Reports Topline Results from P-II…
January 3, 2025

Read more

INSIGHTS+

Most Viewed Articles of 2024 

2024, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.      Top 20 Medical Device Companies of 2024   Shots:    Bringing innovation and technology to healthcare, the…
January 2, 2025

Read more

New Drug Designations - November 2024
INSIGHTS+

New Drug Designations – November 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, and NMPA   The November 2024 report covers designations granted to 28 drugs and 3 devices, encompassing 9 small molecules, 6 biologics, 7 cell and gene therapies as well as 3 medical devices  Significant trends…
December 31, 2024

Read more

Viewpoints_Jay Anders
VIEWPOINTS

Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots

Shots:  Nearly half of FDA-approved AI medical devices lack testing on real patient data, raising significant concerns about patient safety.  PharmaShots welcomes Jay Anders, CMO of Medicomp Systems, to discuss AI implementation trends in healthcare and strategies for ethical AI adoption by healthcare professionals.  Jay emphasizes the importance of clinical validations to ensure the safe…
December 23, 2024

Read more

Load more